The Board of Directors (“Directors” or “Board”) of Livingstone Health Holdings Limited (“Livingstone Health”, or the “Company” and together with its subsidiaries, the “Group”) refers to the announcement dated 15 September 2021 and wishes to provide an update that:
- Since 28 September, more than 1,000 doses of SINOVAC Biotech Ltd’s (“Sinovac””) CoronaVac® vaccine (the “Sinovac Vaccines”) have been administered after receiving up to 7,000 registrations within the first week. The vaccinations have been administered at three clinics under Phoenix Medical Group (“PMG”), the Group’s primary healthcare arm, and have been fully booked until the first half of October 2021;
- Approximately 23% of registrants for the Sinovac Vaccines are aged above 60, 40% aged 40 – 60 and 21% aged 30 – 40; and
- Due to the higher-than-expected registrations, the Group has increased resources to improve the booking system and the availability of vaccination slots to ensure effective vaccination rollout at the clinic.
In addition to its own clinics, the Group has also delivered more than 30,000 out of 101,000 doses to other parties within the first week. The Group would like to assure its patients that there is sufficient vaccines for administration.
Given the high registration rate, the Group has prepared a central call team to reach out to all registrants, while PMG clinics have increased the number of nurses, ushers and doctors to accommodate the vaccine administration.
Crowd control measures have been implemented to ensure the safety of patients and staff, such as no walk-ins and advisories to assure patients that there is sufficient stock of the vaccines. Staff and doctors have also been trained to look out for potential adverse reactions and how to manage them.
Barring unforeseen circumstances, the Group expects the administration of vaccines to contribute positively to the revenue of the Group for the current financial year ending 31 March 2022.
BY ORDER OF THE BOARD
Dr Tay Ching Yit, Wilson
Chief Executive Officer
30 September 2021
This announcement has been reviewed by the Company’s sponsor, SAC Capital Private Limited (“Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGXST”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Ms. Tay Sim Yee at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, Telephone (65) 6232 3210